Description

Travoprost

Travoprost is a high-purity prostaglandin F2α analog used in ophthalmic pharmaceutical formulations for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It functions by increasing the outflow of aqueous humor through both the uveoscleral and trabecular meshwork pathways, offering potent and long-lasting intraocular pressure control. Travoprost
• Is a pharmaceutical-grade prostaglandin analog for ophthalmic formulations
• Is used to lower intraocular pressure in glaucoma and ocular hypertension
• Provides sustained action with once-daily dosing
• Is suitable for sterile ophthalmic solutions and combination therapies
• Is manufactured under Good Manufacturing Practice (GMP) certified conditions
• Is supplied with complete regulatory documentation including Certificate of Analysis (CoA) and technical data
Travoprost is chemically designated as (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid isopropyl ester. It appears as a colorless to pale yellow oil that is insoluble in water but soluble in ethanol and organic solvents suitable for ophthalmic formulation.
In pharmaceutical applications, Travoprost is used in:
• Ophthalmic solutions for open-angle glaucoma and ocular hypertension
• Combination products with beta-blockers or carbonic anhydrase inhibitors
• Research and clinical formulations for ocular pressure management
• Compounded ophthalmic preparations requiring prostaglandin analogs
• Investigational development of long-acting and preservative-free eye drops
Travoprost exerts its therapeutic effect by mimicking the natural prostaglandin F2α, enhancing aqueous humor outflow and maintaining consistent intraocular pressure reduction. It offers a favorable safety profile and high patient compliance with once-daily dosing.
CarboMer supplies Travoprost with control over assay, purity, stereochemical configuration, and residual solvents. The material is suitable for regulated pharmaceutical development and ophthalmic formulation.
The material is packaged in sealed, light-resistant, tamper-evident containers. It is available in laboratory, pilot, and commercial-scale volumes. Minimum order quantities (MOQ), lead times, and documentation—including CoA and SDS—are provided upon request.
Each batch is tested for identity (IR, HPLC), assay, optical purity, residual solvents, and stability under photolytic conditions. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and full traceability documentation accompany every shipment.
As with all CarboMer ophthalmic APIs, Travoprost is supported by formulation guidance, regulatory expertise, and dependable global supply to ensure safe, effective, and compliant pharmaceutical products.